Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
71.86
+2.68 (3.87%)
At close: Mar 9, 2026, 4:00 PM EDT
73.29
+1.43 (1.99%)
After-hours: Mar 9, 2026, 5:11 PM EDT
Inhibrx Biosciences Revenue
Inhibrx Biosciences had revenue of $1.40M in the twelve months ending September 30, 2025, down -19.26% year-over-year. In the year 2024, Inhibrx Biosciences had annual revenue of $200.00K, down -88.89%.
Revenue (ttm)
$1.40M
Revenue Growth
-19.26%
P/S Ratio
719.71
Revenue / Employee
$8,696
Employees
161
Market Cap
1.05B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 200.00K | -1.60M | -88.89% |
| Dec 31, 2023 | 1.80M | 485.00K | 36.88% |
| Dec 31, 2022 | 1.32M | -5.92M | -81.81% |
| Dec 31, 2021 | 7.23M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionINBX News
- 7 days ago - Inhibrx Announces Participation in Upcoming Scientific Conference - PRNewsWire
- 6 weeks ago - These 20 stocks are strong choices for momentum investors - Market Watch
- 7 weeks ago - Inhibrx: Ozekibart Beyond Chondrosarcoma, With Other Targeted Indications, Too - Seeking Alpha
- 2 months ago - Why Inhibrx's Recent Strength May Not Be Built to Last - Benzinga
- 2 months ago - Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program - PRNewsWire
- 4 months ago - Inhibrx Reports Third Quarter 2025 Financial Results - PRNewsWire
- 4 months ago - Inhibrx Announces Participation in Upcoming Scientific Conferences - PRNewsWire
- 4 months ago - Inhibrx: Positive Ozekibart Data For Bone Cancer Leads To Q2 2026 BLA Filing - Seeking Alpha